BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/22/2024 11:33:24 AM | Browse: 60 | Download: 246
 |
Received |
|
2023-12-30 22:29 |
|
Peer-Review Started |
|
2023-12-30 22:29 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-01-23 22:36 |
|
Revised |
|
2024-02-18 13:26 |
|
Second Decision |
|
2024-04-03 01:38 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-04-03 07:02 |
|
Articles in Press |
|
2024-04-03 07:02 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-05-11 02:54 |
|
Publish the Manuscript Online |
|
2024-05-22 11:33 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Chencheng Xie, Naim Alkhouri and Mohamed A Elfeki |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mohamed A Elfeki, MD, MSc, Assistant Professor, Department of Internal Medicine, University of South Dakota Sanford School of Medicine, 1315 S Cliff Ave, Plaza 3, Suite 1200, Sioux Falls, SD 57105, United States. m_elfiky@hotmail.com |
| Key Words |
Metabolic dysfunction-associated steatotic liver disease; Metabolic dysfunction-associated steatohepatitis; Glucagon-like peptide-1; Glucose-dependent inulinotropic polypeptide; Glucagon; Incretin; Receptor agonist |
| Core Tip |
In this review, we highlight the evolving role of incretin and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease. These agents showed promising potential for improving hepatic steatosis and metabolic dysfunction-associated steatohepatitis (MASH) with a clear benefit for associated cardiometabolic risk factors. However, its role in MASH-associated fibrosis remains unclear. Barriers to access due to limited supplies, cost, and lack of insurance coverage could be overcome through patent and regulatory reforms on drug-device combinations, which may allow for generic competitors of these agents to be available for patients at affordable prices. |
| Publish Date |
2024-05-22 11:33 |
| Citation |
<p>Xie C, Alkhouri N, Elfeki MA. Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges. <i>World J Hepatol</i> 2024; 16(5): 731-750</p> |
| URL |
https://www.wjgnet.com/1948-5182/full/v16/i5/731.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v16.i5.731 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
